Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as EXS21546 Powder for Oral Suspension
EXS21546 for · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| EXS21546 Powder for Oral Suspension | EXPERIMENTAL | EXS21546 Powder for Oral Suspension |
| Placebo | PLACEBO_COMPARATOR | Placebo Powder for Oral Suspension |
| EXS21546 Granule in Capsule | EXPERIMENTAL | EXS21546 Granule in Capsule |
| Name | Type | Description |
|---|---|---|
| EXS21546 Powder for Oral Suspension | DRUG | EXS21546 Powder for Oral Suspension |
| EXS21546 Granule in Capsule | DRUG | EXS21546 Granule in Capsule |
| Midazolam | OTHER | Interaction |
| Food Effect | OTHER | Fed/Fasted |
| Placebo Powder for Oral Suspension | OTHER | Placebo Powder for Oral Suspension |
Inclusion Criteria: * BMI 18.0 to 30.0 kg/m2 * Weight ≥60 kg * Must adhere to contraception requirements Exclusion Criteria: * Subjects who have received any IMP in a clinical research study within the 90 days prior to Day 1 * Subjects who have previously been administered IMP in this study. * Ev...
EXS21546 is an investigational small molecule developed by Recursion Pharmaceuticals, Inc. (ticker RXRX) for oncology. It is a powder for oral suspension and has been studied in a Phase 1 clinical trial. It is not an approved medicine and remains in clinical development.
EXS21546 is being developed for oncology indications. Its only recorded clinical study enrolled healthy adult male volunteers rather than patients, so the trial evaluated safety, tolerability, pharmacokinetics and pharmacodynamics rather than antitumor activity. The drug is investigational and has no approved use.
EXS21546 is developed by Recursion Pharmaceuticals, Inc., which trades on the Nasdaq under the ticker RXRX. The company sponsored the Phase 1 study of the compound conducted in the United Kingdom.
EXS21546 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are ongoing. The study was a randomized, double-blind, placebo-controlled three-part trial that enrolled 64 participants. EXS21546 is investigational and has not been approved by the FDA.
EXS21546 has been studied in one completed Phase 1 trial, NCT04727138, titled a 3-part study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of EXS21546. It enrolled 64 healthy male volunteers aged 18 years and older in the United Kingdom. No trials are currently active.
Yes. EXS21546 Powder for Oral Suspension is another name for EXS21546, the investigational oncology small molecule from Recursion Pharmaceuticals, Inc. (RXRX). The oral suspension is the formulation used in its Phase 1 clinical study.